A randomized prospective study to assess the role of topical tacrolimus as preventive therapy in unstable acral vitiligo
Journal of the European Academy of Dermatology and Venereology · 2023
DOI: 10.1111/jdv.19362 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2023. Verfasst von Deepak Kumar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Venereology, and Leprology, Post Graduate Institute of Medical Education and Research, Chandigarh, India. Hauptthemen laut MEDLINE: Tacrolimus, Vitiligo. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
Background
Acral vitiligo is a significantly distressing condition and tends to be treatment‐resistant. The occurrence of new lesions on acral areas further causes greater psychological trauma. Topical tacrolimus has been widely used in the management of vitiligo and its role in preventing flares in other dermatoses such as atopic dermatitis has been well documented.
Objectives
To assess the role of topical tacrolimus as preventive therapy in unstable acral vitiligo. Materials and Methods In this single‐centre randomized prospective study, 60 patients aged 16–60 years having unstable acral vitiligo with symmetrical lesions were enrolled and randomized (1:1) into two groups. Patients in group A were instructed to apply topical tacrolimus 0.1% ointment on both vitiliginous and normal skin while patients in group B were instructed to apply topical tacrolimus 0.1% ointment only on vitiliginous skin for 6 months. Only the distal hand till the wrist joint was chosen for observation. Vitiliginous patches were assessed monthly for 6 months for a change in the number of lesions and total area involved, extension of preexisting lesions and adverse effects if any.
Results
A reduction in the number of lesions was observed in both groups. The decrease in the number of lesions in group A was 5.6% as compared to 2.3% in group B ( p ‐0.001). The decrease in depigmented area in group A was 10.5% as compared to 4.6% in group B ( p ‐0.048). Treatment failure was seen in 11 out of 60 (18.3%) patients.
Conclusion
Tacrolimus 0.1% ointment application showed effectiveness in preventing the appearance of new lesions in unstable acral vitiligo and hastening the repigmentation when applied on both lesional and perilesional skin in vitiligo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Venereology, and Leprology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
ORCID-Profile: Vishal Thakur, Kiruthika Subburaj, Anuradha Bishnoi, Keshavamurthy Vinay, Muthu Sendhil Kumaran, Davinder Parsad
Zitieren
APA
Kumar, D., Thakur, V., Subburaj, K., Bishnoi, A., Vinay, K., Sendhil Kumaran, M., & Parsad, D. (2023). A randomized prospective study to assess the role of topical tacrolimus as preventive therapy in unstable acral vitiligo. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19362
Vancouver
Kumar D, Thakur V, Subburaj K, Bishnoi A, Vinay K, Sendhil Kumaran M, et al. A randomized prospective study to assess the role of topical tacrolimus as preventive therapy in unstable acral vitiligo. Journal of the European Academy of Dermatology and Venereology. 2023. doi:10.1111/jdv.19362
BibTeX
@article{Kumar2023,
author = {Kumar, Deepak and Thakur, Vishal and Subburaj, Kiruthika and Bishnoi, Anuradha and Vinay, Keshavamurthy and Sendhil Kumaran, Muthu and Parsad, Davinder},
title = {A randomized prospective study to assess the role of topical tacrolimus as preventive therapy in unstable acral vitiligo},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2023},
doi = {10.1111/jdv.19362}
}
EUVIMED